Open Access Open Access  Restricted Access Subscription Access
Open Access Open Access Open Access  Restricted Access Restricted Access Subscription Access

MCP-1 Serum Levels were Higher in Patient with Diabetic Nephropathy among Balinese


Affiliations
1 Lecturer, Faculty of Medicine and Health Sciences, Warmadewa University, Jl. Terompong No. 24 Denpasar, Bali, Indonesia
2 Lecturer, Tabanan General Hospital, Jl. Pahlawan no 14, Tabanan, Indonesia
3 Lecturer, Sanjiwani General Hospital. Jl. CiungWenara No 2 Gianyar, Bali, Indonesia
4 Lecturer, Faculty of Medicine, Public Health, and Nursing, Gadjah Mada University, Jl. Farmako, Sekip Utara, Yogyakarta, Indonesia
     

   Subscribe/Renew Journal


Background and Aim: Diabetic nephropathy is a complication of diabetes mellitus which can lead to kidney failure. Monocyte Chemoattractant Protein-1 (MCP-1) is a protein that is expected to be a biomarker of diabetic nephropathy. The purpose of this study was to examined the relationship of MCP-1 with diabetic nephropathy in Indonesia, especially in Bali therefore the accuracy in detecting diabetic nephropathy can be assessed. Method: One hundred and sixteen patients with type 2 diabetes mellitus with diabetic nephropathy (n = 37) and without diabetic nephropathy (n = 79) were included in this study. MCP-1 serum was examined using the enzyme-linked immunosorbent assay (ELISA) method. Result: MCP-1 serum levels were significantly higher in patients with diabetic nephropathy (p <0.001). Analysis of receiver operating characteristic (ROC) curve for diabetic nephropathy detection showed that cut-off point of MCP-1 serum was 436 pg/ml with a sensitivity of 83.7% and 84.8% specificity. Conclusion: It can be concluded that MCP-1serum can be considered as a biomarker for detection of diabetic nephropathy.

Keywords

MCP-1 serum, diabetic nephropathy, biomarker
Subscription Login to verify subscription
User
Notifications
Font Size


Abstract Views: 428

PDF Views: 0




  • MCP-1 Serum Levels were Higher in Patient with Diabetic Nephropathy among Balinese

Abstract Views: 428  |  PDF Views: 0

Authors

Asri Lestarini
Lecturer, Faculty of Medicine and Health Sciences, Warmadewa University, Jl. Terompong No. 24 Denpasar, Bali, Indonesia
AA Sri Agung Aryastuti
Lecturer, Faculty of Medicine and Health Sciences, Warmadewa University, Jl. Terompong No. 24 Denpasar, Bali, Indonesia
Ni Putu Diah Witari
Lecturer, Faculty of Medicine and Health Sciences, Warmadewa University, Jl. Terompong No. 24 Denpasar, Bali, Indonesia
I Wayan Sutarka
Lecturer, Tabanan General Hospital, Jl. Pahlawan no 14, Tabanan, Indonesia
Ni Wayan Sri Wardani
Lecturer, Sanjiwani General Hospital. Jl. CiungWenara No 2 Gianyar, Bali, Indonesia
Pramudji Hastuti
Lecturer, Faculty of Medicine, Public Health, and Nursing, Gadjah Mada University, Jl. Farmako, Sekip Utara, Yogyakarta, Indonesia
Ahmad Hamim Sadewa
Lecturer, Faculty of Medicine, Public Health, and Nursing, Gadjah Mada University, Jl. Farmako, Sekip Utara, Yogyakarta, Indonesia

Abstract


Background and Aim: Diabetic nephropathy is a complication of diabetes mellitus which can lead to kidney failure. Monocyte Chemoattractant Protein-1 (MCP-1) is a protein that is expected to be a biomarker of diabetic nephropathy. The purpose of this study was to examined the relationship of MCP-1 with diabetic nephropathy in Indonesia, especially in Bali therefore the accuracy in detecting diabetic nephropathy can be assessed. Method: One hundred and sixteen patients with type 2 diabetes mellitus with diabetic nephropathy (n = 37) and without diabetic nephropathy (n = 79) were included in this study. MCP-1 serum was examined using the enzyme-linked immunosorbent assay (ELISA) method. Result: MCP-1 serum levels were significantly higher in patients with diabetic nephropathy (p <0.001). Analysis of receiver operating characteristic (ROC) curve for diabetic nephropathy detection showed that cut-off point of MCP-1 serum was 436 pg/ml with a sensitivity of 83.7% and 84.8% specificity. Conclusion: It can be concluded that MCP-1serum can be considered as a biomarker for detection of diabetic nephropathy.

Keywords


MCP-1 serum, diabetic nephropathy, biomarker



DOI: https://doi.org/10.37506/v11%2Fi2%2F2020%2Fijphrd%2F195029